Missouri lawmakers passed a bill last week that would prevent state licensing boards from disciplining physicians who prescribe the wonder drugs Ivermectin and hydroxychloroquine. The bill also prohibits pharmacists from questioning the prescription and its effectiveness.
Missouri legislature passed HB 2149, which modifies provisions relating to professional licensing with a vote of 139-4 last week, according to The Kansas City Star. The legislation now heads to the governor’s desk for his consideration.
According to this bill, “The act of lawfully dispensing, prescribing, administering, or otherwise distributing ivermectin tablets or hydroxychloroquine sulfate tablets for human use shall not be grounds for denial, suspension, revocation, or other disciplinary action by the board.”
“The board shall not deny, revoke, or suspend, or otherwise take any disciplinary action against, a certificate of registration or authority, permit, or license required by this chapter for any person due to the lawful dispensing, distributing, or selling of ivermectin tablets or hydroxychloroquine sulfate tablets for human use in accordance with prescriber directions. A pharmacist shall not contact the prescribing physician or the patient to dispute the efficacy of ivermectin tablets or hydroxychloroquine sulfate tablets for human use unless the physician or patient inquires of the pharmacist about the efficacy of ivermectin tablets or hydroxychloroquine sulfate tablets.”
The Kansas City Star reported:
Sen. Rick Brattin, a Harrisonville Republican, told The Star Thursday he added the amendment after he spoke with doctors who worried they would lose their medical licenses for prescribing the drugs. Brattin, who said he previously bought ivermectin for COVID-19 but has never taken it, described the drug as “politicized.”
“Unfortunately, because of the politicization of those two drugs, [doctors are] being targeted,” he said. “I wanted to protect them from that.”
The Gateway Pundit previously reported that a citywide prevention program using ivermectin as prophylaxis for COVID-19 in Itajaí, Brazil, significantly reduced COVID-19 infection, hospitalization, and death rates. The ivermectin non-users were two times more likely to die of COVID-19 than ivermectin users in the overall population analysis.
Japan’s Kowa company also found Ivermectin has an “antiviral effect” against Omicron and other COVID-19 variants as Phase III clinical trials continue, Reuters reported.
According to the press release, there were no side effects observed with the three doses of ivermectin tested up to 100 μg/kg in continuous administration over 1 month in healthy volunteers.
A study posted in the American Journal of Medicine in January found that early treatment of coronavirus patients with hydroxychloroquine lowered the mortality rate for the disease.
The c19hcq.com website tracks all of the international studies on hydroxychloroquine and its effects on the coronavirus.
According to the website, there are now 416 HCQ COVID-19 studies, 318 peer-reviewed, 343 comparing treatment and control groups. HCQ is not effective when used very late with high dosages over a long period (RECOVERY/SOLIDARITY), effectiveness improves with earlier usage and improved dosing. Early treatment consistently shows positive effects. Negative evaluations typically ignore treatment time, often focusing on a subset of late-stage studies.